A randomized, open-label, multi-center study to evaluate the efficacy of nilotinib versus best supportive care with or without a tyrosine kinase inhibitor (investigator's choice) in adult patients with gastrointestinal stromal tumors resistant to both imatinib and sunitinib

Trial Profile

A randomized, open-label, multi-center study to evaluate the efficacy of nilotinib versus best supportive care with or without a tyrosine kinase inhibitor (investigator's choice) in adult patients with gastrointestinal stromal tumors resistant to both imatinib and sunitinib

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Aug 2016

At a glance

  • Drugs Nilotinib (Primary) ; Imatinib; Sunitinib
  • Indications Gastrointestinal stromal tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms ENEST
  • Sponsors Novartis
  • Most Recent Events

    • 23 Jun 2012 Additional location (Belgium) added as reported by European Clinical Trials Database record.
    • 12 Feb 2012 Results published in the Annals of Oncology.
    • 04 Oct 2011 Actual end date of the extension trial (NCT00488150) is June 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top